Vibeke Wewer

Vibeke Wewer

Auto-generated profile, based on publicly available information

Vibeke Wewer

The Paediatric Department, Copenhagen University Hospital, Hvidovre, Denmark

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
CJC. Jakobsen
C. Jakobsen
Isabelle CleynenIsabelle Cleynen
Isabelle Cleynen
PAP.S. Andersen
P.S. Andersen
SVSeverine Vermeire
Severine Vermeire
PMP. Munkholm
P. Munkholm
VWV. Wewer
V. Wewer
To investigate the association between known inflammatory bowel disease (IBD)-associated genetic variants and development of paediatric IBD, and specific clinical sub-phenotypes. In this case-control study we included IBD patients <18 years of age at diagnosis from the Danish National Patient Registry and healthy children <18 years of age were randomly selected from the Danish Central Office of Civil Registration. The latter had filled out a questionnaire regarding health status, and DNA was obtained from blood samples and the buccal mucosa. Patient files were retrieved and clinical information was extracted. DNA was obtained from Guthrie cards from the Danish National Neonatal Screening Biobank (PKU-biobanken) at Statens Serum Institut and from blood samples. A total of 588 IBD patients (244 Crohn's disease (CD), 318 ulcerative colitis (UC) and 26 IBD-unclassified (IBDU)) and 543 healthy controls were included. We found an association between CD and rs22411880 (ATG16L1, odds ratio (OR)=1.7 [1.1-1.7], p=0.003), rs5743289 (NOD2, OR=1.4 [1.1-1.9], p=0.009) and the paediatric specific rs1250550 (ZMIZ1, OR=0.7 [0.5-0.9], p=0.01). None of the investigated 41 SNPs were associated with disease localisation, medical treatment or surgery after correcting for multiple analyses. We found an association between CD and three previously published genetic variants and replicated the association with the paediatric specific ZMIZ1 gene. No Bonferroni corrected significant genotype-phenotype associations were found. For future studies aimed at finding predictors for disease course in (paediatric) IBD, it will be worthwhile to include a combination of genetic, clinical and serological markers.

3 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSamira Salihovic
Samira Salihovic
NNNiklas Nyström
Niklas Nyström
CMCharlotte Bache-Wiig Mathisen
Charlotte Bache-Wiig Mathisen
RKRobert Kruse
Robert Kruse
COChristine Olbjørn
Christine Olbjørn
JHJonas Halfvarson
Jonas Halfvarson
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.

1 July 2009 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
TRT. Ruuska
T. Ruuska
VWV. Wewer
V. Wewer
FLFredrik Lindgren
Fredrik Lindgren
PMP. Malmborg
P. Malmborg
MLM. Lindquist
M. Lindquist
JGJ. Grönlund
J. Grönlund
The purpose of the study was to collect data on granulocyte-monocyte adsorptive apheresis (GMA) for the treatment of corticosteroid-dependent (SD) or corticosteroid-resistant (SR) inflammatory bowel disease (IBD) in children from 3 Nordic countries to evaluate its efficacy and safety and to assess practical issues. Retrospective data on 37 children treated with GMA were collected. In all, 22 children had ulcerative colitis (UC), 13 Crohn's disease (CD), and 2 had indeterminate colitis (IC). Their mean age was 13.2 years, range 5–17 years, and mean duration of disease was 2.4 years, range 1 month to 6 years. Indication for treatment in the UC group was SD in 11 cases, SR in 6 cases, and other reasons in 5 cases. The corresponding numbers in the CD group were SD in 8 cases, SR in 2 cases, and other reasons in 3 cases. In the IC group, 1 had SD and 1 was refractory to steroids, azathioprine, and infliximab. Efficacy was evaluated by severity indices: the Pediatric Ulcerative Colitis Activity Index (PUCAI) and the Pediatric Crohn's Disease Activity Index (PCDAI) and tapering of corticosteroids. PUCAI and PCDAI decreased significantly in both groups after 3 months (P = 0.0007, P = 0.025). The dosage of corticosteroid was significantly reduced in the UC group by the end of GMA (P = 0.004) and this response continued after 3 months. Relapse was seen in 2 patients with UC and 3 patients with CD after 3 months follow-up. GMA seems to be an effective and safe treatment in 81% of the SD or SR pediatric IBD patients, especially in those with UC.

10 June 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
RNRie Louise Møller Nordestgaard
Rie Louise Møller Nordestgaard
MWMads Damsgaard Wewer
Mads Damsgaard Wewer
MMMikkel Malham
Mikkel Malham
VWVibeke Wewer
Vibeke Wewer
TBTrine Boysen
Trine Boysen
JBJohan Burisch
Johan Burisch
Summary: Background: Paediatric‐onset and elderly‐onset inflammatory bowel disease (IBD) present unique treatment challenges.Aims: We investigated treatment patterns following a first and second course of systemic steroids in paediatric‐ and elderly‐onset IBD and compared them to adult‐onset IBD.Methods: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan–Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid‐sparing medications.Results: 1851 CD (13%) and 1687 (6%) UC patients were paediatric‐onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly‐onset. Paediatric‐onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52–1.77, UC: HR: 2.29, CI: 2.02–2.61] and biologics [CD: HR: 1.43, CI: 1.25–1.65, UC: HR: 1.27, CI: 0.99–1.64], while elderly‐onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35–0.44, UC: HR: 0.58, CI: 0.50–0.67] and biologics [CD: HR: 0.19, CI: 0.14–0.25, UC: HR: 0.36, CI: 0.27–0.48] compared to adult‐onset age groups. After two courses of systemic steroids, elderly‐onset still received less steroid‐sparing medications. High frailty was associated with lower usage of medications for elderly‐onset.Conclusion: There are significant differences in the use of steroid‐sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly‐onset IBD.

25 September 1997 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
VWV. Wewer
V. Wewer
CSC. Strandberg
C. Strandberg
APA. Pærregaard
A. Pærregaard
PKP. A. Krasilnikoff
P. A. Krasilnikoff

1 October 2010 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
NPNatalia Pedersen
Natalia Pedersen
DDDana Duricova
Dana Duricova
MLMartin Lenicek
Martin Lenicek
MEMargarita Elkjaer
Margarita Elkjaer
MBMartin Bortlik
Martin Bortlik
PMPia Munkholm
Pia Munkholm
Infliximab dependency in children with Crohn's disease (CD) has recently been described and found to be associated with a decreased surgery rate. To assess infliximab dependency of adult CD patients, evaluate the impact on surgery, and search for possible clinical and genetic predictors. Two hundred and forty-five CD patients treated with infliximab were included from Danish and Czech Crohn Colitis Database (1999-2006). Infliximab response was assessed as immediate outcome, 1 month after infliximab start: complete, partial, and no response. Three months outcome, after last intended infusion: prolonged response (maintenance of complete/partial response), infliximab dependency (relapse requiring repeated infusions to regain complete/partial response or need of infliximab >12 months to sustain response). Forty-seven percent obtained prolonged response, 29% were infliximab dependent and 24% nonresponders. The cumulative probability of surgery 40 months after infliximab start was 20% in prolonged responders, 23% in infliximab-dependent patients and 76% in nonresponders (P<0.001). The cumulative probability of surgery at 40 months in patients on maintenance versus on demand regime was 33 and 31%, respectively (P=0.63). No relevant clinical or genetic predictors were identified. The infliximab dependency response seems to be equivalent to the prolonged response in adult CD patients when comparing surgery rates.